Discounted Cash Flow
Skinhealth Systems Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $166.6m | $-1.6m | $1.7m | -1.0% | $-0.05 |
| 2020 | $119.1m (-28.5%) | $-1.1m (32.2%) | $-12.4m (-819.7%) | -0.9% (5.1%) | $-0.85 (-1600.0%) |
| 2021 | $260.1m (118.4%) | $-375.1m (-33652.8%) | $-44.0m (-253.6%) | -144.2% (-15355.2%) | $-3.67 (-331.8%) |
| 2022 | $365.9m (40.7%) | $44.4m (111.8%) | $-124.0m (-182.0%) | 12.1% (108.4%) | $0.30 (108.2%) |
| 2023 | $398.0m (8.8%) | $-100.1m (-325.6%) | $8.7m (107.0%) | -25.2% (-307.4%) | $-0.76 (-352.8%) |
| 2024 | $334.3m (-16.0%) | $-29.1m (70.9%) | $9.3m (7.3%) | -8.7% (65.4%) | $-0.23 (69.1%) |
| 2025 | $300.8m (-10.0%) | $-9.5m (67.3%) | $32.3m (246.1%) | -3.2% (63.6%) | $-0.08 (67.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.